What Happened?
Jersey City, NJ-based AsclepiX-Therapeutics Appointed Kevin Slawin as Chief Executive Officer
About the Company
AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.
About the Person
Kevin Slawin is Chief Executive Officer at AsclepiX Therapeutics. Previously, Kevin held various senior HR leadership roles in the industry.
Info Source
News
Short Profile